Inventurus Knowledge Solutions Limited (IKS Health) has officially announced a further investment of up to USD 40 million in its wholly-owned subsidiary, Inventurus Knowledge Solutions, Inc. (IKS Inc). The Board of Directors approved this additional capital infusion during their meeting on March 13, 2026, to support the subsidiary’s ongoing operational and strategic requirements. This investment follows a previous tranche of USD 20 million, and the company plans to deploy the remaining balance in due course while maintaining its 100% shareholding in the US-based entity.

The additional investment into IKS Inc is structured as a capital contribution to strengthen the subsidiary’s ability to deliver high-quality healthcare support services in the North American market. IKS Inc, incorporated in Delaware since 2006, serves as a pivotal arm for the company’s international operations, focusing on medical coding, clinical documentation, and revenue cycle management. The board’s decision emphasizes the group’s commitment to scaling its presence in the United States, where it assists large healthcare providers in optimizing their clinical and financial workflows.

IKS Health is a leading provider of care enablement platforms, offering technology-driven solutions to over 600 health systems and medical groups across the US, Canada, and Australia. In early 2025, the company made significant strides in AI innovation, launching its “Agentic AI Care Enablement Platform” to automate administrative burdens and improve clinical efficiency. Recent updates from 2025 include winning the Black Book survey’s top honors for AI-driven Revenue Cycle Management and securing new partnerships with major specialty groups like StrideCare and VitalMD. The company also successfully transitioned into a publicly listed entity following its major IPO in late 2024, which received a subscription of over 52 times.

For the quarter ended December 31, 2025, Inventurus Knowledge Solutions reported robust financial growth, with net sales reaching ₹820.50 Crores, representing a 19.93% increase compared to ₹684.14 Crores in the corresponding quarter of the previous year. The company’s Profit After Tax (PAT) for the same period stood at ₹183.33 Crores, a substantial growth of 41.37% year-on-year from ₹129.68 Crores in Q3 FY24. This growth was driven by expanded client relationships and the scaling of AI-based documentation services. Notably, the company is backed by the family of the late legendary investor Rakesh Jhunjhunwala; as of March 2025, Rekha Jhunjhunwala and associated discretionary trusts held a significant minority stake in the firm. Other prominent institutional investors include Fidelity Funds and the Government Pension Fund Global.